Have you had moderate to severe atopic dermatitis for at least 1 year?
A clinical trial designed to evaluate the safety and effectiveness of a new investigational medication under development for adult patients with moderate-to-severe atopic dermatitis is currently being conducted.
All subjects will receive injections of trial medication every other week for up to 32 weeks. For all trial participants, the trial will include up to 20 visits to the trial clinic.
Atopic Dermatitis (AD) is a chronic inflammatory skin disease. In its severe form, AD is characterized by widespread skin lesions, itch, as well as increased risk of skin infections. AD is associated with a substantial burden that typically includes poor quality of life, sleep disturbance, and reductions in work productivity.